MaxCyte IPO Presentation Deck

EXPERTTM Platform Addresses Industry Challenges July 2021 Challenge Development times and cost of viral vectors as delivery method has increased Next-generation cell therapy programs have become increasingly complex Regulatory risk increases with new unknowns (donor cells, 2nd/3rd/4th gen approaches, new indications) Vein-to-vein manufacturing times high; efficiencies needed to deliver medicines to patients faster MaxCyte's Solutions Non-viral approaches address viral vector capacity constraints and safety concerns Flow Electroporation technology facilitates multiplex engineering; challenging with viruses given payload limitations, capacity constraints, and cost FDA Master File can be appended to regulatory filings to reduce regulatory risk EXPERTTM platform provide industry leading efficiency/viability at high scale in 30 minutes or less, enabling manufacturers to quickly scale up production CONFIDENTIAL M MaxCyte 10

View entire presentation